3.145.17.20
dgid:
enl:
npi:0

Search Results

You are searching for: thyroid eye disease

Some patients with TED need longer to respond to teprotumumab

Patients with thyroid eye disease (TED) treated with teprotumumab may need longer than 12 weeks to see a clinically significant...

Read More

TED Google searches increased 525% after teprotumumab commercial

Direct-to-consumer advertising may have helped to increase public interest for thyroid eye disease (TED), according to researchers who noted an...

Read More

More studies needed on hearing loss linked to teprotumumab use in TED

Due to the potential for hearing loss in patients treated with teprotumumab for thyroid eye disease (TED), baseline audiometry and...

Read More

Analysis compares teprotumumab vs intravenous methylprednisolone vs placebo in TED

Results from a meta-analysis suggest that the use of intravenous methylprednisolone (IVMP) in patients with thyroid eye disease (TED) may...

Read More

Study examines success of lateral orbital wall decompression in pediatric TED

A lateral orbital decompression via a conjunctival incision over the lateral orbital rim without a canthotomy or cantholysis can be...

Read More

Baseline imaging may predict teprotumumab response

Total rectus volume is predictive of proptosis reduction following treatment with teprotumumab in patients with thyroid eye disease (TED), according...

Read More

TED may result in changes across the entire face

A study found that the effects thyroid eye disease (TED) has on soft tissue may expand beyond the orbit and...

Read More

Coupled medical and surgical treatment needed for TED

Despite the session topic focusing on surgery for patients with inactive thyroid eye disease (TED), Louis A Mawn, MD, Professor...

Read More

POLL: Do you believe all TED is inflammatory/active?

During a presentation at AAO 2021 Subspecialty Day, Louis A Mawn, MD, discussed Rundle's curve, a term often used in Graves ophthalmopathy...

Read More

Teprotumumab is a ‘powerful resource’ for ophthalmologists treating TED

During a presentation at AAO Subspecialty Day 2021, Suzanne K. Freitag, MD, Director of the Ophthalmic Plastic Surgery Service at...

Read More

Recalcitrant TED responsive to teprotumumab

Patients with recalcitrant thyroid eye disease (TED) treated with teprotumumab demonstrated a significant improvement in clinical activity score (CAS), proptosis...

Read More

Case Series: TED reactivation after COVID-19 vaccination

Due to the potential risk of autoimmune disease reactivation after COVID-19 vaccination noted by the American College of Rheumatology, researchers...

Read More

Teprotumumab adherence rates are high in patients with TED

Patients with thyroid eye disease (TED) appear to adhere to treatment with teprotumumab in clinical practice like controlled trial findings,...

Read More